RxDoctor Payments DataLook up a doctor →

Anne Edmonds, PA

Surgical · Tulsa, OKNPI 1003352543

Payments from drug & device makers

$14,828in general payments, 2019–2025

Across 748 payments — averaging $19.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Johnson & Johnson$2K
  • Lilly USA, LLC$2K
  • Sun Pharmaceutical Industries Inc.$1K
  • Regeneron Healthcare Solutions, Inc.$1K
  • E.r. Squibb & Sons, L.L.C.$1K
  • plus $5K from 22 others

What the payments were for

  • Food & beverage$14,16896%
  • Education$6604%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,828 in reported general payments places this provider in the 95th percentile of 94 surgical providers in Oklahoma.

See all surgical providers in Oklahoma

Medicare billing

Part B allowed, 2024
$177,507
Medicare patients
891
Services billed
4,364

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CibinqoAbrocitinib13$115,826
OtezlaApremilast16$56,692
Fluorouracil104$6,189
Fluocinonide94$4,718
Ketoconazole212$3,757
Tacrolimus14$2,858
Triamcinolone Acetonide197$2,653
Doxycycline Hyclate127$1,879
Metronidazole26$1,500
Tretinoin12$1,378
Imiquimod46$1,300
Clobetasol Propionate24$1,128
Hydrocortisone70$732
Ciclopirox22$694
Fluconazole15$395

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerCibinqo$637$115,82613 claims
AmgenOtezla$703$56,69216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 94 surgical providers in Oklahoma.

Other surgical in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →